Longevity & AgingSingle-Dose Epigenetic Shot Cuts LDL Cholesterol for 18 Months in Primate Trials
A biotech company called Scribe Therapeutics has received regulatory clearance in Australia to begin human testing of a new cholesterol-lowering treatment called STX-1150. Unlike statins or gene-editing therapies, this approach uses epigenetic silencing — temporarily switching off a gene called PCSK9 that drives LDL cholesterol production — without permanently changing DNA. In primate studies, a single low dose reduced LDL cholesterol by more than 50 percent, and those reductions lasted roughly 18 months. The Phase 1 trial will enroll up to 64 participants across Australia and New Zealand, focusing initially on safety, dosing, and how the body processes the treatment. If human results mirror the animal data, this could eventually offer a long-lasting, non-permanent alternative to daily cholesterol medications.
